Sartorius AG (Sartorius AG) Cash And Cash Equivalents : $1,199 Mil (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Sartorius AG Cash And Cash Equivalents?

Sartorius AG's quarterly cash and cash equivalents increased from Sep. 2023 ($313.66 Mil) to Dec. 2023 ($413.52 Mil) and increased from Dec. 2023 ($413.52 Mil) to Mar. 2024 ($1,198.70 Mil).

Sartorius AG's annual cash and cash equivalents declined from Dec. 2021 ($387.35 Mil) to Dec. 2022 ($175.74 Mil) but then increased from Dec. 2022 ($175.74 Mil) to Dec. 2023 ($413.52 Mil).

Sartorius AG Cash And Cash Equivalents Historical Data

The historical data trend for Sartorius AG's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius AG Cash And Cash Equivalents Chart

Sartorius AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

60.49

247.49

387.35

175.74

413.52

Sartorius AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial															163.06	175.73	313.66	413.52	1,198.70

Sartorius AG Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Sartorius AG (OTCPK:SARTF) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Sartorius AG Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Sartorius AG's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Sartorius AG (Sartorius AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius AG (OTCPK:SARTF) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

SOAGY:USA SSSGY:USA SUVPF:USA 1SRT3:Italy SRT3d:UK 0NIR:UK SRT3:Germany SRT3:Austria

Address

Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079

Website

https://www.sartorius.com

Sartorius AG is a leading provider of bioprocessing solutions. Its Bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology, or SUT. Its Lab Products and Services division offers a wide range of products for lab use, including scales, pipettes, and filtration equipment. As of 2022, the Bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 74% ownership and 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (37% of 2022 sales), the Americas (37%), and Asia-Pacific (26%). We estimate China revenue to be around 10%.